Details
Stereochemistry | ACHIRAL |
Molecular Formula | C21H22O4 |
Molecular Weight | 338.397 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=C(\C=C\C(=O)C2=CC=C(O)C=C2)C=C(C(O)=C1)C(C)(C)C=C
InChI
InChIKey=KAZSKMJFUPEHHW-DHZHZOJOSA-N
InChI=1S/C21H22O4/c1-5-21(2,3)17-12-15(20(25-4)13-19(17)24)8-11-18(23)14-6-9-16(22)10-7-14/h5-13,22,24H,1H2,2-4H3/b11-8+
Molecular Formula | C21H22O4 |
Molecular Weight | 338.397 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Optical Activity | NONE |
Licochalcone A (LicA) is a flavonoid isolated from the famous Chinese medicinal herb Glycyrrhiza uralensis Fisch and has a wide spectrum of pharmacological activities such as anti-oxidant, anti-bacterial, anti-viral, and anti-cancer. However, its pharmacological mechanism is not well defined. The anti-Inflammatory effects of LicA on IL-1β-Stimulated human osteoarthritis chondrocytes was reached by activating Nrf2 signaling pathway. LicA showed anti-proliferative and apoptotic effects in breast cancer cells through regulating Sp1 and apoptosis-related proteins in a dose- and a time-dependent manner. In addition, the chemotherapeutic potential of LicA for treatment of human cervical cancer was achieved by inhibition of PI3K/Akt/mTOR signaling.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: Nrf2 signaling pathway Sources: https://www.ncbi.nlm.nih.gov/pubmed/28756519 |
|||
Target ID: P08047 Gene ID: 6667.0 Gene Symbol: SP1 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/28498645 |
|||
Target ID: map04151 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26311737 |
|||
Target ID: map04150 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26311737 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | Unknown Approved UseUnknown |
|||
Palliative | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Curative | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Anti-human immunodeficiency virus phenolics from licorice. | 1988 Jun |
|
Phenolic constituents of licorice. II. Structures of licopyranocoumarin, licoarylcoumarin and glisoflavone, and inhibitory effects of licorice phenolics on xanthine oxidase. | 1989 Nov |
|
Cytotoxic activity of low molecular weight polyphenols against human oral tumor cell lines. | 2000 Jul-Aug |
|
Transcriptional suppression of the HIV promoter by natural compounds. | 2003 Mar |
|
Natural antimycobacterial metabolites: current status. | 2004 Apr |
|
Inhibition by licochalcone A, a novel flavonoid isolated from liquorice root, of IL-1beta-induced PGE2 production in human skin fibroblasts. | 2005 Dec |
|
Effect of licorice compounds licochalcone A, glabridin and glycyrrhizic acid on growth and virulence properties of Candida albicans. | 2011 Nov |
|
Anti-hepatitis C virus compounds obtained from Glycyrrhiza uralensis and other Glycyrrhiza species. | 2014 Mar |
|
Differential Effects of Glycyrrhiza Species on Genotoxic Estrogen Metabolism: Licochalcone A Downregulates P450 1B1, whereas Isoliquiritigenin Stimulates It. | 2015 Aug 17 |
|
Induction of NAD(P)H:Quinone Oxidoreductase 1 (NQO1) by Glycyrrhiza Species Used for Women's Health: Differential Effects of the Michael Acceptors Isoliquiritigenin and Licochalcone A. | 2015 Nov 16 |
|
Inhibition of human cytochrome P450 enzymes by licochalcone A, a naturally occurring constituent of licorice. | 2015 Oct |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26311737
Nude mice inoculated with Human cervical cancer cell lines (SiHa) were fed with 0, 10, or 20 mg/kg Licochalcone A
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/28957807
It was investigated the anti-osteoarthritic effects of licochalcone A (Lico A) in rat chondrocytes. Polymerase chain reaction and Western blotting were performed to evaluate the expression of a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS)-5, ADAMTS-4, collagen II, matrix metalloproteinase (MMP)-13 and MMP-1 at both the gene and protein levels, respectively. In addition, the wnt/β-catenin and nuclear factor kappa B (NF-κB) signaling pathways were also analyzed by Western blotting. Lico A downregulated ADAMTS-5, ADAMTS-4,MMP-13 and MMP-1 expression, and diminished the IL-1β-induced inhibition of collagen II. In addition, the activation of β-catenin and phosphorylation of p65 and IKKα/β were suppressed by Lico A.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 04:19:05 GMT 2023
by
admin
on
Sat Dec 16 04:19:05 GMT 2023
|
Record UNII |
JTV5467968
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C2189
Created by
admin on Sat Dec 16 04:19:05 GMT 2023 , Edited by admin on Sat Dec 16 04:19:05 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C148179
Created by
admin on Sat Dec 16 04:19:05 GMT 2023 , Edited by admin on Sat Dec 16 04:19:05 GMT 2023
|
PRIMARY | |||
|
m6802
Created by
admin on Sat Dec 16 04:19:05 GMT 2023 , Edited by admin on Sat Dec 16 04:19:05 GMT 2023
|
PRIMARY | Merck Index | ||
|
LICOCHALCONE A
Created by
admin on Sat Dec 16 04:19:05 GMT 2023 , Edited by admin on Sat Dec 16 04:19:05 GMT 2023
|
PRIMARY | |||
|
87080-27-1
Created by
admin on Sat Dec 16 04:19:05 GMT 2023 , Edited by admin on Sat Dec 16 04:19:05 GMT 2023
|
NON-SPECIFIC STEREOCHEMISTRY | |||
|
SUB184387
Created by
admin on Sat Dec 16 04:19:05 GMT 2023 , Edited by admin on Sat Dec 16 04:19:05 GMT 2023
|
PRIMARY | |||
|
5318998
Created by
admin on Sat Dec 16 04:19:05 GMT 2023 , Edited by admin on Sat Dec 16 04:19:05 GMT 2023
|
PRIMARY | |||
|
58749-22-7
Created by
admin on Sat Dec 16 04:19:05 GMT 2023 , Edited by admin on Sat Dec 16 04:19:05 GMT 2023
|
PRIMARY | |||
|
100000170400
Created by
admin on Sat Dec 16 04:19:05 GMT 2023 , Edited by admin on Sat Dec 16 04:19:05 GMT 2023
|
PRIMARY | |||
|
DTXSID10904181
Created by
admin on Sat Dec 16 04:19:05 GMT 2023 , Edited by admin on Sat Dec 16 04:19:05 GMT 2023
|
PRIMARY | |||
|
JTV5467968
Created by
admin on Sat Dec 16 04:19:05 GMT 2023 , Edited by admin on Sat Dec 16 04:19:05 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> ACTIVE CONSTITUENT ALWAYS PRESENT | |||
|
PARENT -> ACTIVE CONSTITUENT ALWAYS PRESENT |
LICOCHALCONE A exhibited antimicrobial activity (MICs 3.13?12.5 ug/ml) against MSSAs (strains FDA 209P and Smith) and MRSAs(strains K3 and ST 28).
|
||
|
PARENT -> ACTIVE CONSTITUENT ALWAYS PRESENT |
Anti-HCV activity IC50 was found to be be 2.5 ug/mL.
|
||
|
PARENT -> ACTIVE CONSTITUENT ALWAYS PRESENT |
0.64% of dry weight of contents.
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |